The review concluded that glucagon-like peptide-1 receptor agonists, compared to insulin glargine, significantly decreased weight in patients with type 2 diabetes, but increased gastrointestinal adverse events. The influence on mortality or diabetes-associated complications remained unclear. The authors' conclusions reflect the limited short-term evidence, but due to limited data and potential for review bias, they should be interpreted with caution.
Study selection
Eligible studies were randomised controlled trials (RCTs) (parallel and crossover designs) of GLP-1 receptor agonist injection compared to long-acting insulin analogue injection in combination with stable doses of an oral antidiabetic drug for more than 12 weeks. Quasi-randomised controlled trials were excluded.
Eligible participants were aged 18 years or more and had type 2 diabetes diagnosed according to World Health Organization (WHO) 1998 or ADA 2009 diagnostic criteria. Primary end point outcomes included mortality (diabetes related or total), diabetes-related adverse events and health-related quality of life (measured by a validated instrument). Secondary outcomes included glycaemic control, plasma lipid levels, fasting and postprandial insulin and C-peptide levels, weight or body mass index (BMI), blood pressure, waist and hip circumference, waist:hip ratio, mild or moderate hypoglycaemia, adverse events and costs.
Participants in the included studies ranged in mean age from 55 to 60 years. The proportion of males ranged from 32% to 70%. Mean BMI ranged from 31 to 35kg/m 2 . Duration of diabetes ranged from four to 10 years. GLP-1 receptor agonists included either exenatide or liraglutide; these were compared with insulin glargine. These treatments were combined with combinations of metformin, sulfonylurea and thiazolidinedione.
Two reviewers independently selected studies for inclusion in the review. Disagreements were resolved by a third reviewer.
Assessment of study quality
The included studies were assessed for quality; criteria included randomisation procedure, allocation concealment, method of blinding, intention to treat (ITT) analysis and selective outcome reporting. For each trial, criteria were scored as adequate (low risk of bias), unclear (uncertain risk of bias) or inadequate (high risk of bias).
The authors did not state how many reviewers performed the quality assessment.
Data extraction
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For each trial, mean differences (MD) were calculated for continuous data and relative risks (RRs) were calculated for dichotomous data, together with 95% confidence intervals (CIs).
The authors did not explicitly state how many reviewers performed data extraction, but did mention that three reviewers were involved in the data extraction process.
Methods of synthesis
A fixed-effect model (or random-effects model where there was evidence of statistical heterogeneity) was used to pool mean differences, relative risks and 95% confidence intervals. Subgroup analysis was performed for different GLP-1 receptor agonists (exenatide and liraglutide). Sensitivity analyses were performed to assess the effect of different types of study design (parallel group or crossover). Statistical heterogeneity was assessed with X 2 and I 2 (substantial heterogeneity was defined as p<0.1 and I 2 >50%). A narrative synthesis was undertaken where data were unsuitable for combining in meta-analyses. Funnel plots of primary outcomes and important secondary outcome were calculated to assess publication bias.
Results of the review
Five RCTs (n=1,452) were included in the review: four trials with a parallel group design and one with a crossover design. All trials had ITT analysis and no indication of selective outcome reporting. None of the trials were blinded. Allocation concealment and randomisation method were adequate for four of the five trials. Trial duration ranged from 16 to 52 weeks.
Primary outcomes
None of the trials assessed mortality or diabetes related complications. One trial in a secondary analysis from another paper found no evidence of a difference in health-related quality of life.
Secondary outcomes
Glycaemic control: Insulin glargine was associated with a significant reduction in fasting blood glucose levels when compared to glucagon-like peptide-1 (GLP-1) receptor agonists (MD 1.31, 95% CI 1.04 to 1.58: I 2 =0%; four trials) and a significantly increased percentage of patients who achieved fasting blood glucose of less than 5.6mmol/L (RR 0.35, 95% CI 0.25 to 0.49: I 2 =0%; three trials). There was no evidence of a difference in the other measures of glycaemic control (change in glycosylated hemoglobin levels and proportion of patients achieving glycosylated hemoglobin ≤7%) between treatments.
Postprandial blood glucose levels (four trials): Three of the trials suggested that GLP-1 receptor agonists were associated with significantly reduced postprandial blood glucose levels when compared with insulin glargine.
Fasting and postprandial insulin and C-peptide levels (three trials): GLP-1 receptor agonists were associated with significantly reduced fasting and postprandial insulin (one trial) and C-peptide levels (two trials).
Plasma lipid levels: GLP-1 receptor agonists were associated with statistically significant reductions in LDL-C levels when compared to insulin glargine (MD -0.18, 95% CI -02.8 to -0.08, I 2 =0%; two trials), but there were no significant differences between treatments for the other lipids (total cholesterol, HDL-C and triglycerides).
Weight or Body Mass Index: Compared to insulin glargine, GLP-1 receptor agonists were associated with significantly greater weight reduction (MD -3.96kg, 95% CI -5.14 to -2.77, I 2 =89%; five trials), significantly reduced systolic blood pressure (MD -3.59mmHg, 95% CI -5.74 to -1.43: I 2 =0%; two trials) and significantly reduced waist circumference (two trials).
Hypoglycaemia: There was no evidence of a significant difference in the overall incidence of hypoglycaemia between treatments, but insulin glargine was associated with significantly more nocturnal hypoglycaemic episodes than GLP-1 receptor agonists (two trials).
Adverse events: GLP-1 receptor agonists were associated with a significantly greater overall incidence of treatment-
